Literature DB >> 24092860

Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN.

Xi-Rui Wang1, Hui Luo, Hai-Lin Li, Lei Cao, Xie-Feng Wang, Wei Yan, Ying-Yi Wang, Jun-Xia Zhang, Tao Jiang, Chun-Sheng Kang, Ning Liu, Yong-Ping You.   

Abstract

BACKGROUND: Altered expression of micro(mi)RNAs has been shown to be associated with tumorigenesis and tumor progression. The expression of phosphatase and tensin homolog (PTEN) plays an important role in glioma and is regarded as a prognostic marker of glioma patients. The goal of this study was to investigate the function of lethal (let)-7a miRNA in glioma cell lines with different PTEN phenotypes.
METHODS: One hundred ninety-eight glioma tissues were used to profile miRNA expression.
RESULTS: Let-7a was shown to have lower expression in high-grade glioma than in low-grade glioma. Low expression of let-7a was correlated with poor prognosis of primary glioblastoma patients. We demonstrated that K-ras was a functional target for let-7a to induce cell cycle arrest, apoptosis, and inhibition of cell migration and invasion in vitro. Our further results showed no difference in malignancy inhibition induced by let-7a in 4 glioma cells, including U87 (PTEN null), U251 (PTEN mutant), LN229 (PTEN wild type), and LN229 (PTEN small interfering RNA). The phosphatidylinositol-3 kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase pathways were inhibited by let-7a, and the inhibition effects had no difference in 4 glioma cells. We demonstrated that let-7a could induce suppression of glioma in vivo by generating a glioma xenograft model.
CONCLUSION: Our results indicated that let-7a suppresses its target transcript K-ras and inhibits glioma malignancy independent of PTEN expression.

Entities:  

Keywords:  K-ras; PTEN; glioma; let-7a; miRNA

Mesh:

Substances:

Year:  2013        PMID: 24092860      PMCID: PMC3813414          DOI: 10.1093/neuonc/not107

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  26 in total

1.  MicroRNA in cancer prognosis.

Authors:  Frank J Slack; Joanne B Weidhaas
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

2.  MicroRNA-221 and -222 regulate radiation sensitivity by targeting the PTEN pathway.

Authors:  Chunzhi Zhang; Chunsheng Kang; Ping Wang; Yongzhen Cao; Zhonghong Lv; Shizhu Yu; Guangxiu Wang; Anling Zhang; Zhifan Jia; Lei Han; Chunying Yang; Hiromichi Ishiyama; Bin S Teh; Bo Xu; Peiyu Pu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-01       Impact factor: 7.038

3.  Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3.

Authors:  Yu Wang; Yiwei Lu; Soo Ting Toh; Wing-Kin Sung; Patrick Tan; Pierce Chow; Alexander Y F Chung; London L P Jooi; Caroline G L Lee
Journal:  J Hepatol       Date:  2010-04-02       Impact factor: 25.083

4.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

5.  Elevated IGFIR expression regulating VEGF and VEGF-C predicts lymph node metastasis in human colorectal cancer.

Authors:  Chunhui Zhang; Li Hao; Liang Wang; Yichuan Xiao; Hailiang Ge; Zhenya Zhu; Yunbao Luo; Yi Zhang; Yanyun Zhang
Journal:  BMC Cancer       Date:  2010-05-07       Impact factor: 4.430

6.  The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras.

Authors:  Wing Pui Tsang; Tim Tak Kwok
Journal:  Carcinogenesis       Date:  2009-04-16       Impact factor: 4.944

7.  Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation.

Authors:  J P Robinson; M W VanBrocklin; A R Guilbeault; D L Signorelli; S Brandner; S L Holmen
Journal:  Oncogene       Date:  2009-10-26       Impact factor: 9.867

8.  GFAP-Cre-mediated activation of oncogenic K-ras results in expansion of the subventricular zone and infiltrating glioma.

Authors:  Ty W Abel; Cara Clark; Brian Bierie; Anna Chytil; Mary Aakre; Agnieszka Gorska; Harold L Moses
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

Review 9.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

10.  The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice.

Authors:  Xiao-Yan He; Jun-xia Chen; Zheng Zhang; Chun-lei Li; Qiong-le Peng; Hui-min Peng
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-22       Impact factor: 4.553

View more
  41 in total

1.  Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.

Authors:  Yang Nan; Liyun Guo; Yunpeng Song; Le Wang; Kai Yu; Qiang Huang; Yue Zhong
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-11       Impact factor: 4.553

2.  Endogenous FOXP3 inhibits cell proliferation, migration and invasion in glioma cells.

Authors:  Biao Zhang; Yuchao Dou; Xinnv Xu; Xiuyu Wang; Bin Xu; Jixiang Du; Qiong Wang; Qingguo Li; Jinhuan Wang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  MiR-622 suppresses proliferation, invasion and migration by directly targeting activating transcription factor 2 in glioma cells.

Authors:  Rui Zhang; Hui Luo; Shuai Wang; Zhengxin Chen; Lingyang Hua; Hong-Wei Wang; Wanghao Chen; Yongsheng Yuan; Xiaobin Zhou; Daqian Li; Shuying Shen; Tao Jiang; Yongping You; Ning Liu; Huibo Wang
Journal:  J Neurooncol       Date:  2014-09-26       Impact factor: 4.130

4.  The tRNA pseudouridine synthase TruB1 regulates the maturation of let-7 miRNA.

Authors:  Ryota Kurimoto; Tomoki Chiba; Yoshiaki Ito; Takahide Matsushima; Yuki Yano; Kohei Miyata; Yuka Yashiro; Tsutomu Suzuki; Kozo Tomita; Hiroshi Asahara
Journal:  EMBO J       Date:  2020-09-14       Impact factor: 11.598

5.  MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras.

Authors:  Zhumei Shi; Qiudan Chen; Chongyong Li; Lin Wang; Xu Qian; Chengfei Jiang; Xue Liu; Xiefeng Wang; Hai Li; Chunsheng Kang; Tao Jiang; Ling-Zhi Liu; Yongping You; Ning Liu; Bing-Hua Jiang
Journal:  Neuro Oncol       Date:  2014-05-25       Impact factor: 12.300

6.  * Glioblastoma Exosomes for Therapeutic Angiogenesis in Peripheral Ischemia.

Authors:  Anthony Monteforte; Brian Lam; Michael B Sherman; Kayla Henderson; Andrew D Sligar; Adrianne Spencer; Brian Tang; Andrew K Dunn; Aaron B Baker
Journal:  Tissue Eng Part A       Date:  2017-11       Impact factor: 3.845

Review 7.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

8.  Let-7a regulates mammosphere formation capacity through Ras/NF-κB and Ras/MAPK/ERK pathway in breast cancer stem cells.

Authors:  Chongwen Xu; Xin Sun; Sida Qin; Huangzhen Wang; Zhiwei Zheng; Shaohua Xu; Gang Luo; Peng Liu; Jian Liu; Ning Du; Yunfeng Zhang; Dapeng Liu; Hong Ren
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2.

Authors:  Yang Li; Xianfeng Zhang; Dawei Chen; Chengyuan Ma
Journal:  Tumour Biol       Date:  2015-12-29

10.  The Emerging Field of Noncoding RNAs and Their Importance in Pediatric Diseases.

Authors:  Rui Zhou; Piyush Joshi; Keisuke Katsushima; Weihong Liang; Wei Liu; Neil A Goldenberg; George Dover; Ranjan J Perera
Journal:  J Pediatr       Date:  2020-06       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.